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Edited by Hans-Dieter KlenkAbstract The herpesvirus life cycle has two distinct phases:
latency and lytic replication. The viral immediate early protein
replication and transcription activator (RTA) plays a central role
in mediating the balance between these two phases. Here, we
demonstrate that a B cell terminal diﬀerentiation factor X-box
binding protein 1 (XBP-1) can eﬀectively initiates Kaposi’s sar-
coma-associated herpesvirus (KSHV) reactivation by activating
the RTA promoter, which results in the induction of other viral
lytic transcripts. We also showed splicing of the XBP-1 mRNA
which speciﬁcally occurs during B cell diﬀerentiation is critical in
triggering KSHV reactivation. This work demonstrates the inte-
gration of KSHV reactivation mechanisms with host cell diﬀer-
entiation.
 2007 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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X-box binding protein 1 (XBP-1) is a transcription factor re-
quired for B cell terminal diﬀerentiation and is expressed at
high levels in plasma cells [1–3]. XBP-1 belongs to the
CREB/ATF family of transcription factors, and binds prefera-
bly to the CRE-like element and some TPA-response elements.
During B cell terminal diﬀerentiation, IRE1-dependent splic-
ing takes place, leading to removal of a 26-nucleotide intron
in the transcript. This process creates a frameshift, which re-
sults in a mRNA encoding a 371 amino acid protein that acts
as a highly active transcription factor with an addition of a
transactivation domain in the carboxyl terminus [4,5]. Splicing
of XBP-1 leads to the activation of unfolded protein response
(UPR) to support the high level of Ig production [1,6]. This
spliced form (XBP-1s), but not the unspliced form (XBP-1u),
forms an autoregulatory loop with IL-6, whose production
supports plasma cell growth and survival [1,7].*Corresponding author. Fax: +1 310 794 5123.
E-mail address: rsun@mednet.ucla.edu (R. Sun).
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doi:10.1016/j.febslet.2007.06.056Lympho-tropic gamma-herpesviruses including Epstein Barr
Virus (EBV) and Kaposi’s sarcoma-associated herpesvirus
(KSHV) are linked with several lymphomas and lymphoprolif-
erative diseases. These viruses can establish long-term latency
in memory B cells. Under certain conditions they can undergo
reactivation, resulting in production of infectious virion parti-
cles, a process important for transmission, maintenance of per-
sistent infection and pathogenesis [8,9]. Recent reports showed
that host cell terminal diﬀerentiation is associated with the ini-
tiation of reactivation [10–13]. The terminal diﬀerentiation of
tonsil B cells into plasma cells can initiate EBV reactivation
in vivo [10]. Moreover, the KSHV-infected monotypic (IgM
lambda) plasmablasts in multicentric Castleman disease
(MCD) have high levels of both hIL-6 and vIL-6 expression
and KSHV lytic gene expression [11,13,14].
The viral immediate-early protein replication and transcrip-
tion activator (RTA) is both necessary and suﬃcient for
KSHV reactivation. RTA expression is the ﬁrst event occur-
ring during KSHV lytic replication [15]. RTA activates down-
stream lytic promoters as well as its own promoter [16–18].
Polyadenylated nuclear RNA (PAN, also called nut-1) is the
most abundant downstream lytic transcript induced by RTA
expression [19,20]. RTA also activates the cellular IL-6 pro-
moter, which itself can stimulate KSHV lytic replication in in-
fected lymphoma cell lines. These ﬁndings thus suggested a
connection between KSHV reactivation and B cell terminal
diﬀerentiation which involves the regulation of IL-6 [17,21].
XBP-1 was identiﬁed as one of the cDNA clones that can in-
duce KSHV reactivation in a genome-wide screen to systemat-
ically identify cellular factors that induce KSHV reactivation
in B cells. In this screen, the ability of over 26000 full-length
cDNA expression clones to induce KSHV reactivation were
individually assessed [22,23]. This report presents the data
demonstrating the role of the spliced form of XBP-1 in activat-
ing KSHV RTA and other lytic gene expression, markers for
KSHV reactivation.2. Study design
2.1. Transfection, Western blots and RT-Q-PCR
KSHV RTA cDNA was expressed in the pFLAG-CMV2 vector.
Plasmids encoding spliced (XBP-1s) or unspliced (XBP-1u) variantsblished by Elsevier B.V. All rights reserved.
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Fig. 1. Induction of KSHV lytic transcripts in KS-1 cells by XBP-1.
KS-1 cells were transfected with increasing amount of XBP-1s or XBP-
1u (0.2 lg, 0.5 lg or 1.25 lg of cDNA per 106 cells in a 12-well plate).
Transfection of RTA (1.25 lg) served as a positive control. Cells were
harvested 24 h after incubation. Total cellular RNAs were isolated
from the transfected cells and reverse transcribed. The C(T) value was
normalized against GAPDH and the fold induction was calculated by
using the formula y = 2DC(T). All data points fall in the linear range of
each primer set.
3486 F. Yu et al. / FEBS Letters 581 (2007) 3485–3488of mouse XBP-1 were generated by Laurie Glimcher [1]. KS-1 and
DG-75 cells were transfected using Lipofectamine 2000 (Invitrogen)
and electroporation respectively. Rabbit polyclonal antibody against
KSHV lytic antigen K8 (gift from Jae Jung) was used for Western blot
analysis. For RT-Q-PCR analysis, RNA was reverse transcribed using
SuperScript II (Invitrogen). The Q-PCR primers were: ORF50-F (5 0-
CACAAAAATGGCGCAAGATGA-3 0) and ORF50-R (5 0-TGGTA-
GAGTTGGGCCTTCAGTT-3 0); PAN-F (5 0-GCCGCTTCTGGT-
TTTCATTG-3 0) and PAN-R (5 0-TTGCCAAAAGCGACGCA-30);
GAPDH-F (5 0-GAAGGTGAAGGTCGGAGTC-3 0) and GAPDH-R
(5 0-GAAGATGGTGATGGGATTTC-3 0) [24].
2.2. Reporter assay
The reporter pPAN-122luc (pLUC/-122) contains the nucleotides
122 to +14 of the KSHV PAN promoter region in pGL3-basic vector
(Promega) [20], and the reporter pRpluc contains the 3 kb region up-
stream of the KSHV RTA coding sequence in pGL2-basic vector (Pro-
mega) [25]. Renilla luciferase reporter pRL-SV40 was used as internal
transfection control. For reporter assays in KS-1 cells, the indicated
amount of XBP-1s or XBP-1u cDNA was cotransfected with 25 ng
of pRpluc or PAN-122luc, and 1 ng of pRL-SV40 per 2.5 · 105 cells
in 48-well plate. For 293T cells, 50 ng pRpluc and 2 ng pRL-SV40
per 5 · 105 cells were used in 24-well plate. For DG-75 cells, 0.5 lg
pRpluc or PAN-122luc and 0.4 lg pRL-SV40 per 107 cells were used.
Dual-Luciferase assays (Promega) were carried out 24 h (for KS-1 cells
and 293T cells) or 48 h (DG-75 cells) after transfection.XBP-1s          XBP-1u
+    –
K8
Actin
Fig. 2. Induction of KSHV lytic protein K8 expression in KS-1 cells
by XBP-1. KS-1 cells were transfected with increasing amount of XBP-
1s or XBP-1u (0.2 lg, 0.5 lg or 1.25 lg of cDNA per 106 cells in a 12-
well plate). Transfection of RTA (1.25 lg) served as a positive control
(+) and transfection of vector as negative control (). Cells were
harvested 24 h after incubation.3. Results and discussion
To determine whether XBP-1 expression can induce KSHV
reactivation, viral transcripts and antigens were measured in
KSHV latently-infected primary eﬀusion lymphoma (PEL)
cells KS-1 after transfection with plasmids encoding XBP-1s
or XBP-1u. The reverse transcription-quantitative-PCR (RT-
Q-PCR) results demonstrated a strong dose-dependent upreg-
ulation of RTA and PAN (Fig. 1). An induction of 24-fold and
57-fold for the RTA and PAN transcripts was observed respec-RTA promoter activation in KS-1 cells
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Fig. 3. Activation of KSHV lytic promoters by XBP-1s. Shown here are reporter assays on the RTA promoter (A) and PAN promoter (B) in KS-1
cells, the RTA promoter (C) and PAN promoter (E) in DG-75 cells, and the RTA promoter in 293T cells (D). Dual-Luciferase assay was performed
and the relative luciferase activity was compared to vector-transfected cells, whose luciferase intensity was set as 1. Transfection with RTA cDNA
was used as a positive control.
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tein level, Western blot analysis in KS-1 cells showed dose-
dependant induction of KSHV lytic antigen K8 by transfection
of the plasmid expressing XBP-1s, but not XBP-1u (Fig. 2).
The RTA cDNA expression plasmid was included in both
experiments as a positive control. XBP-1s was able to induce
lytic gene expression to a comparable level as RTA, indicating
XBP-1 can provide a very strong signal to induce KSHV reac-
tivation. Our results also demonstrate that the splicing of
XBP-1 is critical for its ability to induce KSHV reactivation,
as the unspliced form XBP-1u did not induce lytic gene expres-
sion.
To determine the step at which XBP-1s induces KSHV reac-
tivation, luciferase reporter assays were conducted to measure
the promoter activities of RTA and PAN. Expression from the
PAN promoter has previously been shown to be highly sensi-
tive to RTA expression [20]. We observed that XBP-1s induced
the RTA and PAN promoters approximately 37- and 280-fold
in KS-1 cells (Fig. 3). In KS-1 cells where the viral genome is
present, both RTA and PAN promoter were strongly activated
by XBP-1s, indicating eﬃcient activation of viral lytic promot-
ers upon XBP-1s expression (Fig. 3A and B). In virus-free
DG-75 and 293T cells, XBP-1s was still capable of activating
the RTA promoter 3–5-fold, a level comparable to RTA
(Fig. 3C and D), suggesting that in the absence of auto-activa-
tion by endogenous RTA, activation of the RTA promoter by
XBP-1 is independent of viral factors or B cell-speciﬁc factors.
In infected cells, endogenous RTA is expressed from the viral
genome, providing an auto-stimulatory loop which then may
enhance the XBP-1s-mediated RTA promoter activity. In con-
trast, the PAN promoter could not be activated by XBP-1s in
DG-75 cells (Fig. 3E), indicating that PAN promoter activa-
tion likely results from the expression of endogenous RTA
protein. Expression of XBP-1s did not further enhance activa-
tion of the PAN promoter by RTA in 293T cells, indicating
XBP-1s functions upstream of RTA activation (data not
shown).
The ability of XBP-1 to initiate KSHV lytic gene expression
uncovered in this study establishes a mechanistic link between
KSHV reactivation and B cell diﬀerentiation. The signiﬁcance
of this observation is further enhanced by an independent ﬁnd-
ing that XBP-1 plays a critical role in EBV reactivation sug-
gesting a conserved mechanism in reactivation among
gamma-herpesvirus family members [26]. It is necessary and
advantageous for the virus to respond to terminal diﬀerentia-
tion and initiate productive replication before the host cell
dies. Furthermore, diﬀerentiation of B cells into plasma cells
provides a better cellular environment for viral replication to
maximize virus production [27]. This study provides insight
into the exploitation of host cell diﬀerentiation process by lym-
pho-tropic herpesviruses, which will facilitate the understand-
ing of associated pathogenesis.
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